Lateral Flow Immunoassay Validated for Detection of Cryptococcal Antigen
|
By LabMedica International staff writers Posted on 23 Feb 2015 |

Image: The CrAg lateral flow assay to detect cryptococcal antigens (Photo courtesy of Immuno-Mycologics).
Cryptococcosis is an important and potentially lethal opportunistic infection in immunocompromised patients, especially in human immunodeficiency virus (HIV) infected and organ transplant patients.
The incidence of the infection in non-HIV immunocompromised patients caused by Cryptococcus neoformans and in immunocompetent patients caused by C. gattii has increased in developed countries.
Medical microbiologists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) compared a lateral flow immunoassay (LFA) to a currently used enzyme immunoassay for detection of cryptococcal antigen in 396 sera and 651 cerebrospinal fluid specimens. The cryptococcal antigen detection was performed in retrospective and prospective sera and CSF specimens collected from March 2010 to August 2012 in patients suspected of cryptococcal infection from the Johns Hopkins Hospital, an academic tertiary care hospital.
The newly developed CrAg lateral flow immunoassay (LFA) (Immuno-Mycologics [IMMY]; Norman, OK, USA) offers a rapid and easy alternative detection platform. The LFA assay detects glucuronoxylomannan (GXM), the major polysaccharide component of the cryptococcal capsule. It is a dipstick sandwich immunochromatographic assay that captures the GXM by gold-conjugated anti-Cryptococcus monoclonal antibodies incorporated on the dipstick membrane. This test was compared with an enzyme immunoassay (EIA) from Meridian Premier (Meridian Biosciences; Cincinnati, OH, USA).
The scientists found 97% concordance between the two assays. The LFA assay detected an additional 22 positives. Overall, the LFA had sensitivity of 100% and specificity of 99.6% for the diagnosis of cryptococcosis. Although reading the LFA result can be subjective, they found that the visible lines suggestive of positive results are usually easy to determine. Easy readability combined with additional advantages of rapid turn-around time of 10-minutes ease of performance, requiring little technical expertise, and limited cost make the LFA an attractive tool for routine laboratory use.
The authors concluded that the IMMY LFA showed better sensitivity in detecting C. neoformans antigen in serum and CSF specimens compared to an EIA method in current use. Because of the enhanced sensitivity, users must be aware of the possibility of false positive results in patients with low clinical suspicion of cryptococcal infection. The LFA is rapid, accurate, easy to perform, and cost-effective, and thus it is attractive for implementation by clinical laboratories for routine patient care testing. The study was published on January 31, 2015, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins University School of Medicine
Immuno-Mycologics
Meridian Biosciences
The incidence of the infection in non-HIV immunocompromised patients caused by Cryptococcus neoformans and in immunocompetent patients caused by C. gattii has increased in developed countries.
Medical microbiologists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) compared a lateral flow immunoassay (LFA) to a currently used enzyme immunoassay for detection of cryptococcal antigen in 396 sera and 651 cerebrospinal fluid specimens. The cryptococcal antigen detection was performed in retrospective and prospective sera and CSF specimens collected from March 2010 to August 2012 in patients suspected of cryptococcal infection from the Johns Hopkins Hospital, an academic tertiary care hospital.
The newly developed CrAg lateral flow immunoassay (LFA) (Immuno-Mycologics [IMMY]; Norman, OK, USA) offers a rapid and easy alternative detection platform. The LFA assay detects glucuronoxylomannan (GXM), the major polysaccharide component of the cryptococcal capsule. It is a dipstick sandwich immunochromatographic assay that captures the GXM by gold-conjugated anti-Cryptococcus monoclonal antibodies incorporated on the dipstick membrane. This test was compared with an enzyme immunoassay (EIA) from Meridian Premier (Meridian Biosciences; Cincinnati, OH, USA).
The scientists found 97% concordance between the two assays. The LFA assay detected an additional 22 positives. Overall, the LFA had sensitivity of 100% and specificity of 99.6% for the diagnosis of cryptococcosis. Although reading the LFA result can be subjective, they found that the visible lines suggestive of positive results are usually easy to determine. Easy readability combined with additional advantages of rapid turn-around time of 10-minutes ease of performance, requiring little technical expertise, and limited cost make the LFA an attractive tool for routine laboratory use.
The authors concluded that the IMMY LFA showed better sensitivity in detecting C. neoformans antigen in serum and CSF specimens compared to an EIA method in current use. Because of the enhanced sensitivity, users must be aware of the possibility of false positive results in patients with low clinical suspicion of cryptococcal infection. The LFA is rapid, accurate, easy to perform, and cost-effective, and thus it is attractive for implementation by clinical laboratories for routine patient care testing. The study was published on January 31, 2015, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins University School of Medicine
Immuno-Mycologics
Meridian Biosciences
Latest Microbiology News
- Complete Malaria Genomes Could Improve Species Identification and Surveillance
- Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
- Automated Microbial Identification and Susceptibility System Gains FDA Clearance
- Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
- Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
- Common Genetic Variant Increases Risk of Bacterial Pneumonia
- Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
- Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
- Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Channels
Clinical Chemistry
view channel
Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
Parkinson’s disease can be difficult to diagnose before movement symptoms appear, highlighting the need for earlier detection methods. Researchers have explored whether metabolic changes in sebum, the... Read more
AI Predicts Kidney Stone Composition From Routine Urine Tests
Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. Identifying stone composition is important for guiding treatment... Read moreMolecular Diagnostics
view channel
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more
Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
Fapon showcased its AI-engineered enzymes, reverse transcription technologies, and nucleic acid library preparation solutions at the Association for Molecular Pathology (AMP) 2026 Annual Meeting &... Read moreAMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







